<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Multiple sclerosis: Pregnancy planning</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Multiple sclerosis: Pregnancy planning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Multiple sclerosis: Pregnancy planning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Men-Jean Lee, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cathlyn Sullivan, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Graves, MD, PhD, MAS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H528989350"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system that is a leading cause of neurologic disability. MS disproportionally affects women more than men by a ratio of approximately 2:1 to 3:1, and the mean age of onset of MS is approximately 30 years. In general, the prevalence of MS is highest in North America and European nations and lowest in Asia, Oceania, and South America. The symptoms of MS are commonly present in women of reproductive age, who need special considerations for pregnancy. (See  <a class="medical medical_review" href="/d/html/96016.html" rel="external">"Pathogenesis and epidemiology of multiple sclerosis"</a>.)</p><p>This topic will include reproductive goals and fertility planning, assessment of MS disease activity, the need for disease-modifying therapies (DMTs), the effect of MS on pregnancy, the effect of pregnancy on changing the course of MS, DMT washout, and the use of DMTs in pregnancy. Care during pregnancy and the postpartum period is reviewed separately. (See  <a class="medical medical_review" href="/d/html/138599.html" rel="external">"Multiple sclerosis: Pregnancy and postpartum care"</a>.)</p><p>Other aspects of MS are discussed elsewhere:</p><p> <a class="medical medical_review" href="/d/html/1691.html" rel="external">Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis</a><br/> <a class="medical medical_review" href="/d/html/96029.html" rel="external">Clinical presentation, course, and prognosis of multiple sclerosis in adults</a><br/> <a class="medical medical_review" href="/d/html/1688.html" rel="external">Evaluation and diagnosis of multiple sclerosis in adults</a><br/> <a class="medical medical_review" href="/d/html/1689.html" rel="external">Manifestations of multiple sclerosis in adults</a><br/> <a class="medical medical_review" href="/d/html/1690.html" rel="external">Symptom management of multiple sclerosis in adults</a><br/> <a class="medical medical_review" href="/d/html/1698.html" rel="external">Treatment of acute exacerbations of multiple sclerosis in adults</a><br/> <a class="medical medical_review" href="/d/html/1687.html" rel="external">Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults</a><br/> <a class="medical medical_review" href="/d/html/129095.html" rel="external">Indications for switching or stopping disease-modifying therapy for multiple sclerosis</a><br/> <a class="medical medical_review" href="/d/html/1686.html" rel="external">Treatment of secondary progressive multiple sclerosis in adults</a><br/> <a class="medical medical_review" href="/d/html/128298.html" rel="external">Treatment of primary progressive multiple sclerosis in adults</a><br/> <a class="medical medical_review" href="/d/html/129091.html" rel="external">Overview of disease-modifying therapies for multiple sclerosis</a></p><p class="headingAnchor" id="H594668228"><span class="h1">PRECONCEPTION PLANNING AND CARE</span></p><p class="headingAnchor" id="H2503841618"><span class="h2">Counseling</span><span class="headingEndMark"> — </span>Counseling for women with MS is an important aspect of optimizing pregnancy outcomes [<a href="#rid1">1</a>]. Ideally, preconception counseling should take place with the reproductive partner soon after the diagnosis of MS. Preconception counseling should include reassurance that, in general, pregnancy does not negatively affect MS disease progression.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of pregnancy</strong> – The optimal time for pregnancy is when MS symptoms are stable, since MS disease stability is associated with better intrapartum and postpartum outcomes. Unless premature ovarian failure is a concern, conception is generally not recommended until one to two years after MS diagnosis to allow the disease to be adequately controlled. However, older women or women who have other reasons to conceive shortly after the diagnosis of MS can be readily supported through this process.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraception</strong> – Patients should be informed that contraception has not been shown to negatively affect MS course and that the disease itself does not interact with hormonal contraception [<a href="#rid2">2</a>]. In fact, the use of high-dose estrogen, as found in oral contraceptive pills, with interferon (IFN)-beta has been shown to reduce the rate of formation of new T2 magnetic resonance imaging (MRI) lesions, which are thought to work synergistically to promote an anti-inflammatory effect [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preconception and prenatal care</strong> – Preconception recommendations are to avoid alcohol and smoking, eat a balanced diet, take vitamin D supplementation, and prioritize sleep hygiene. Vitamin D levels less than 12 ng/mL (30 nmol/L) in early pregnancy have been associated with two times the risk of MS in the child [<a href="#rid4">4</a>]. Approximately 1000 to 2000 units/day of vitamin D supplementation prior to pregnancy would result in optimal vitamin D levels of 40 to 60 ng/mL during pregnancy [<a href="#rid5">5,6</a>]. (See  <a class="medical medical_review" href="/d/html/130920.html" rel="external">"Nutrition in pregnancy: Assessment and counseling"</a> and  <a class="medical medical_review" href="/d/html/453.html" rel="external">"Nutrition in pregnancy: Dietary requirements and supplements"</a>.)</p><p></p><p class="bulletIndent1">Live vaccines should be avoided in pregnant women with MS. Inactivated vaccines can be used safely. Polysaccharide pneumococcal and hepatitis B vaccines are safe in pregnancy if needed. Bacterial vaccines (Bacillus Calmette-Guerin and typhoid) and attenuated virus vaccines (measles, mumps, rubella [MMR]; varicella-zoster; and rotavirus) are safe in preconception and the third trimester of pregnancy [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/442.html" rel="external">"Immunizations during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of MS transmission to offspring</strong> – Some parents are concerned that their children might inherit MS [<a href="#rid8">8</a>]. While MS is not a genetically inherited disease, it is believed to be caused by the interaction of genetic susceptibility factors and environmental triggers. The overall risk of developing MS in the general population is low (0.1 to 0.3 percent) [<a href="#rid9">9,10</a>]. Having a first-degree relative (eg, parent) with MS is associated with an increased risk of 2 to 4 percent [<a href="#rid11">11,12</a>]. Thus, mothers and fathers with MS should be aware of the increased genetic risk.</p><p></p><p class="bulletIndent1">The strongest genetic factor for MS is human leukocyte antigen (HLA) DRB1*15, and this gene explains approximately 10 percent of the genetic risk of the disease. An analysis of genetic data from over 47,000 individuals with MS and 68,000 control subjects found 200 autosomal susceptibility variants for MS outside the major histocompatibility complex (MHC), 31 susceptibility variants within the MHC, and one susceptibility locus on the X chromosome X [<a href="#rid13">13</a>]. Altogether, genetic variants explain approximately 49 percent of MS heritability [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">Known environmental risk factors for MS are smoking tobacco, low vitamin D, and the Epstein-Barr virus [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/96016.html" rel="external">"Pathogenesis and epidemiology of multiple sclerosis", section on 'Epidemiology and risk factors'</a>.)</p><p></p><p class="headingAnchor" id="H1841731322"><span class="h2">Use of disease-modifying therapies (DMTs)</span><span class="headingEndMark"> — </span>Women of reproductive age with severe MS symptoms should be encouraged to use DMTs [<a href="#rid9">9</a>]. However, given beneficial effects of pregnancy on relapse rate, DMTs may be stopped in pregnancy for some women. For women who desire to become pregnant (or for men who are using <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a>), the risk of possible adverse effects of DMTs on the fetus must be weighed against DMT discontinuation and increased risk of maternal disease relapses. Practitioners should discuss the benefits and risks of DMTs commonly used to treat MS, including the effects of DMTs before, during, and after pregnancy.</p><p>The overall goal should be to minimize risk of the reactivation of MS by shortening the "washout period" (the time without any DMT to allow the levels of the drug to be eliminated from the maternal system) as much as possible in preconception and managing any risk of rebound relapse associated with stopping a lymphocyte sequestering agent (eg, <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a>, sphingosine 1-phosphate receptor [S1PR] drugs). (See <a class="local">'DMT washout'</a> below.)</p><p>Forty-nine percent of women surveyed responded they felt "inadequately informed" about DMT in pregnancy [<a href="#rid15">15</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guidance for women</strong> – Most experts advise that women discontinue treatment with DMTs for MS if possible when they are planning a pregnancy and during pregnancy [<a href="#rid16">16-19</a>]. Ideally, pregnancy would be scheduled for a time when MS activity has been quiescent for a year [<a href="#rid19">19</a>]. Prior to attempting pregnancy, a washout period is advised for some DMTs  (<a class="graphic graphic_table graphicRef138581" href="/d/graphic/138581.html" rel="external">table 1</a>). (See <a class="local">'DMT washout'</a> below.)</p><p></p><p class="bulletIndent1">To minimize the time off DMT, it may be helpful to use menstrual cycle charting, basal body temperature monitoring, and ovulation predictor kit or ultrasound measurement of follicle size to improve the odds of conception [<a href="#rid20">20</a>]. Referral to a fertility specialist is suggested for women with demyelinating disease if conception is not achieved within six months [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/7437.html" rel="external">"Evaluation of the menstrual cycle and timing of ovulation"</a> and  <a class="medical medical_review" href="/d/html/5411.html" rel="external">"Natural fertility and impact of lifestyle factors", section on 'How do I know if I am in my fertile period?'</a> and  <a class="medical medical_review" href="/d/html/7396.html" rel="external">"Overview of infertility"</a> and  <a class="medical medical_review" href="/d/html/5445.html" rel="external">"Female infertility: Evaluation"</a>.)</p><p></p><p class="bulletIndent1">Most MS experts agree, supported by registry data, that the older injectable DMTs (ie, beta interferons and <a class="drug drug_general" data-topicid="8490" href="/d/drug information/8490.html" rel="external">glatiramer acetate</a>) can be continued while trying to conceive with careful planning and counseling. Otherwise, the approach to DMT use in pregnancy varies among MS clinicians. Those who favor stopping DMTs argue that only limited evidence is available concerning their safety during pregnancy, that the MS relapse rate is much reduced in pregnancy regardless (see <a class="local">'MS activity in pregnancy and postpartum'</a> below), and that DMTs can be started or restarted in the immediate postpartum period. Other experts argue that the decision must weigh uncertain risks to the fetus posed by DMTs for MS against clear benefits to the mother. The available data do <strong>not</strong> support aborting pregnancy because of concerns regarding DMT exposure, even with exposure to DMTs with the highest theoretical risk [<a href="#rid21">21-23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of DMT use during pregnancy</strong> – Some drugs used to treat MS are known teratogens, including <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a> and <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>; others are potential teratogens, including <a class="drug drug_general" data-topicid="16078" href="/d/drug information/16078.html" rel="external">fingolimod</a>, <a class="drug drug_general" data-topicid="120818" href="/d/drug information/120818.html" rel="external">siponimod</a>, and <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>. Such drugs are contraindicated in pregnant women or women of childbearing potential who are not using reliable contraception.</p><p></p><p class="bulletIndent1">In addition, oral DMTs are relatively contraindicated during pregnancy and breastfeeding, related to the mechanism of delivery (bioavailable to the fetus in the blood stream) and mechanism of action  (<a class="graphic graphic_table graphicRef138591" href="/d/graphic/138591.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">A systematic review searched the literature through February 2012 and identified 15 studies (four prospective cohort, five retrospective cohort, and six case series) that evaluated pregnancies exposed to IFN-beta drugs (n = 761), <a class="drug drug_general" data-topicid="8490" href="/d/drug information/8490.html" rel="external">glatiramer acetate</a> (n = 97), and <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> (n = 35) [<a href="#rid21">21</a>]. IFN-beta exposure was associated with lower mean birth weight, shorter mean birth length, and preterm birth (&lt;37 weeks) but was <strong>not</strong> associated with spontaneous abortion, cesarean delivery, birth weight &lt;2500 g, lower mean gestational age, or congenital anomaly. Glatiramer acetate exposure was <strong>not</strong> associated with lower mean birth weight, lower mean gestational age, preterm birth (&lt;37 weeks), congenital anomaly, or spontaneous abortion. Natalizumab exposure was <strong>not</strong> associated with lower mean birth weight, shorter mean birth length, or lower mean gestational age. There were no studies reporting exposure to <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>, <a class="drug drug_general" data-topicid="88899" href="/d/drug information/88899.html" rel="external">dimethyl fumarate</a>, <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>, <a class="drug drug_general" data-topicid="16078" href="/d/drug information/16078.html" rel="external">fingolimod</a>, or <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a> during pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of DMT discontinuation</strong> – An analysis of data from the observational MSBase Registry, with 1998 pregnancies from 1619 women with MS treated in the time period after 2011, found that discontinuation of <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> or <a class="drug drug_general" data-topicid="16078" href="/d/drug information/16078.html" rel="external">fingolimod</a> was associated with an increased intrapartum and postpartum relapse rate [<a href="#rid24">24</a>]; continuation of natalizumab during pregnancy was associated with reduced odds of relapse. Postpartum resumption of high-efficacy DMTs (eg, natalizumab) was associated with a reduced hazard of postpartum relapse. This observational study did not include women treated with anti-CD20 monoclonal antibodies.</p><p></p><p class="bulletIndent1">An earlier series of women with MS found that exposure to DMTs for at least eight weeks during pregnancy (n = 61) was associated with a significantly lower postpartum MS relapse rate and a lower postpartum risk of disease progression compared with pregnancies not exposed (n = 89) [<a href="#rid25">25</a>]. The MS relapse rate was significantly lower for both the exposed and unexposed groups during pregnancy compared with the baseline relapse rate prior to pregnancy. These findings are limited by the retrospective, nonrandomized nature and small size of this study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Highly active disease</strong> – For patients with highly active MS, the benefit of continuing DMT up to conception or throughout pregnancy to prevent relapses may be greater than the risk of fetal harm. Among the DMTs, <a class="drug drug_general" data-topicid="8490" href="/d/drug information/8490.html" rel="external">glatiramer acetate</a> may be used during conception and pregnancy, as extensive safety data suggest it is not associated with fetal harm [<a href="#rid20">20,21,26,27</a>]. IFN-beta preparations are also considered relatively safe during pregnancy and are not associated with an increased risk of congenital anomalies [<a href="#rid21">21,28</a>].</p><p></p><p class="bulletIndent1">If required, <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> can continue throughout pregnancy with a reduced infusion regimen of every six to eight weeks [<a href="#rid20">20</a>]. Natalizumab has not been associated with significant fetal harm when continued through pregnancy [<a href="#rid29">29-31</a>] but does cross the placenta; natalizumab use during the second or third trimester, primarily after 25 weeks, is associated with a risk of transient thrombocytopenia and anemia.</p><p></p><p>However, since most women stop DMT prior to pregnancy or in the first trimester, available data for DMT exposure through pregnancy are limited [<a href="#rid32">32</a>]; more data are awaited from ongoing registries.</p><p class="headingAnchor" id="H4036985092"><span class="h2">DMT washout</span><span class="headingEndMark"> — </span>A "washout period" refers to the estimated length of time the DMT should be stopped before pregnancy to reduce the risk of fetal harm  (<a class="graphic graphic_table graphicRef138581" href="/d/graphic/138581.html" rel="external">table 1</a>) [<a href="#rid17">17,20</a>]. The goal is to time the washout period to end as close as possible to conception. Minimizing the total time off therapy before a positive pregnancy test makes relapse during pregnancy less likely. It is imperative to counsel patients on the length of washout and to establish when the medication was stopped. DMT washout applies to breastfeeding as well as pregnancy. In addition, counseling about the risk of rebound relapse, which is higher for certain medications such as <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> and the S1PR modulators, should be weighed against fetal teratogenicity in a shared decision-making model with the patient.</p><p>The length of the washout period varies among therapies based upon the half-life of the medication  (<a class="graphic graphic_table graphicRef138581" href="/d/graphic/138581.html" rel="external">table 1</a>), although the optimal length of washout is not firmly established for the different DMTs [<a href="#rid17">17,20,33</a>]. The FDA prescription labels recommend the following washout periods:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8490" href="/d/drug information/8490.html" rel="external">Glatiramer acetate</a>, none</p><p class="bulletIndent1"><span class="glyph">●</span>Interferons, none</p><p class="bulletIndent1"><span class="glyph">●</span>Fumarates (<a class="drug drug_general" data-topicid="88899" href="/d/drug information/88899.html" rel="external">dimethyl fumarate</a>, <a class="drug drug_general" data-topicid="123109" href="/d/drug information/123109.html" rel="external">diroximel fumarate</a>, <a class="drug drug_general" data-topicid="128079" href="/d/drug information/128079.html" rel="external">monomethyl fumarate</a>), none; regardless, some experts use a two-week washout</p><p class="bulletIndent1"><span class="glyph">●</span>S1PR modulators:</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16078" href="/d/drug information/16078.html" rel="external">Fingolimod</a>, two months</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="120818" href="/d/drug information/120818.html" rel="external">Siponimod</a>, 10 days</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="127521" href="/d/drug information/127521.html" rel="external">Ozanimod</a>, three months</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="131158" href="/d/drug information/131158.html" rel="external">Ponesimod</a>, one week</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">Natalizumab</a>, three months</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">Alemtuzumab</a>, four months</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">Ocrelizumab</a>, six months</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">Ofatumumab</a>, six months</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a>, six months</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">Cladribine</a>, six months</p><p></p><p>These washouts may be longer than necessary or practical for <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> and certain B-cell depleting monoclonal antibodies (eg, <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>)  (<a class="graphic graphic_table graphicRef138581" href="/d/graphic/138581.html" rel="external">table 1</a>) [<a href="#rid20">20,34</a>].</p><p><a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">Teriflunomide</a> requires an <strong>active elimination protocol</strong> using oral <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> or activated charcoal to reduce the plasma level to &lt;0.02 mg/L [<a href="#rid35">35,36</a>].</p><p class="headingAnchor" id="H770592890"><span class="h2">Infertility</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infertility risk and MS</strong> – Most women with MS have normal fertility. Observational cohort data suggest that MS is not associated with infertility [<a href="#rid9">9,20,37</a>]. Population-based studies have found that the rates of spontaneous pregnancy and time to pregnancy for patients with MS are similar to the general population [<a href="#rid38">38-40</a>]. As an example, an observational cohort study of 216 pregnancies (n = 84 pregnant patients) reported that the rates of spontaneous pregnancy, time to pregnancy, and miscarriage in women with MS were similar to rates in the general population [<a href="#rid38">38</a>]. This study also found that pregnancy rates may be increasing in the MS population over time. Other studies, limited by small sample sizes, reported factors associated with reduced fertility in women with MS, including altered levels of sex hormones and gonadotrophins, and reduced ovarian reserve characterized by various factors, including lower levels of anti-müllerian hormone [<a href="#rid41">41,42</a>]. However, the data are inconsistent; a large case-control study found that levels of anti-müllerian hormone were similar in women with MS (n = 412) compared with healthy controls (n = 180) [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1">Likewise, there are few data on potential outcomes of pregnancies fathered by men with MS undergoing treatment with DMTs. A large population-based study showed that men with MS on either IFN-beta or <a class="drug drug_general" data-topicid="8490" href="/d/drug information/8490.html" rel="external">glatiramer acetate</a> fathered full-term pregnancies that were appropriate for gestational age [<a href="#rid44">44</a>]. The clinical severity of paternal MS did not correlate with birth outcomes.</p><p></p><p class="bulletIndent1">Immunosuppressants sometimes used in MS, such as <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, have been associated with female infertility and may also affect the male spermatozoa [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sexual dysfunction</strong> – MS may be associated with female and male sexual dysfunction, which could impair family planning, as reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/1689.html" rel="external">"Manifestations of multiple sclerosis in adults", section on 'Sexual dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infertility treatment</strong> – Patients with MS who do not achieve pregnancy after six months of optimal attempts to conceive should be offered referral to a fertility clinic to reduce time off DMT and thereby minimize the risk of MS relapse [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Patients should be counseled about the increased risk of relapse (if off DMT) with assisted reproductive technology (ART), even if the ART cycle is not successful. It is reasonable to continue DMT in the form of IFN-beta, <a class="drug drug_general" data-topicid="8490" href="/d/drug information/8490.html" rel="external">glatiramer acetate</a>, or monoclonal antibodies until the ART cycle is over to decrease risk of relapse [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">ART, especially in the form of gonadotropin-releasing hormone (GnRH) agonists, has been associated with an increased risk of MS relapse and the number or size of T2/gadolinium-enhancing lesions [<a href="#rid39">39,46,47</a>]. GnRH is known to stimulate immune cell proliferation and production of cytokines, chemokines, endothelial growth factors, and estrogen. As an example, a prospective study of 16 women with relapsing-remitting MS (RRMS) treated with 26 ART cycles total showed a sevenfold increased risk of MS exacerbation and a nearly ninefold increased risk of new T2 MRI brain lesions three months after ART [<a href="#rid46">46</a>]. Of note, this and similar studies evaluated mainly women on low-efficacy DMT (<a class="drug drug_general" data-topicid="8490" href="/d/drug information/8490.html" rel="external">glatiramer acetate</a> or IFN-beta) that was stopped before the use of ART [<a href="#rid20">20</a>]. Patients receiving glatiramer acetate or IFN-beta during ART therapy until conception may have a lower relapse rate [<a href="#rid8">8</a>]. Data are needed for relapse rates in patients who were treated with higher-efficacy DMTs (eg, <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>, <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>) before undergoing ART [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H3920734649"><span class="h1">EFFECT OF MS ON PREGNANCY OUTCOMES</span></p><p class="headingAnchor" id="H2833716026"><span class="h2">Maternal outcomes</span><span class="headingEndMark"> — </span>MS does not increase the risk of complications of pregnancy, such as ectopic pregnancy, abnormal placentation, spontaneous miscarriage, antepartum bleeding, pre-eclampsia, stillbirth, premature birth, or congenital malformations. A 2002 population-based cohort study showed that women with MS (n = 1980) were not more likely to have pregnancy or delivery complications compared with the general population of patients without MS [<a href="#rid48">48</a>]. A 2021 cross-sectional study also found no differences in pregnancy-related outcomes among women with MS compared with the general population [<a href="#rid49">49</a>]. There was no difference in pre-eclampsia, gestational diabetes, placenta complications, emergency cesarean section, instrumental delivery, low Apgar score, stillbirth, preterm birth, or congenital malformations. Another study analyzed an inpatient database with an estimated 15 million deliveries in the United States from 2003 to 2006, including 4730 in women with MS [<a href="#rid50">50</a>]. MS was associated with a small increase in the rate of cesarean delivery (42.4 percent versus 32.8 percent for controls, absolute risk difference approximately 9.6 percent, odds ratio [OR] 1.3, 95% CI 1.1-1.4).</p><p class="headingAnchor" id="H2422216770"><span class="h2">Fetal development</span><span class="headingEndMark"> — </span>Fetal anomalies have not been associated with maternal MS in large prospective studies and cross-sectional registries [<a href="#rid49">49,51</a>].</p><p>In data from the United States inpatient database cited above, MS was associated with only a small increase in the risk of intrauterine growth restriction (2.7 percent versus 1.9 percent for controls, absolute risk difference approximately 0.8 percent, OR 1.7, 95% CI 1.2-3.3) [<a href="#rid50">50</a>]. An earlier report from Norway evaluated a nationwide registry of over two million births from 1967 through 2002 and identified 649 births among 461 mothers with MS [<a href="#rid52">52</a>]. Mothers with MS had a higher proportion of infants who were small for gestational age (13.5 versus 11.3 percent, absolute risk difference approximately 2.2 percent, OR 1.45, 95% CI 1.14-1.84).</p><p>The potential risks for teratogenicity in fetal development associated with disease-modifying therapies are reviewed above. (See <a class="local">'Use of disease-modifying therapies (DMTs)'</a> above.)</p><p class="headingAnchor" id="H1937793032"><span class="h1">EFFECT OF PREGNANCY ON MS DISEASE ACTIVITY</span></p><p class="headingAnchor" id="H189269602"><span class="h2">MS phenotypes</span><span class="headingEndMark"> — </span>The core MS phenotypes are those of relapsing-remitting and progressive disease. The pattern and course of MS is further categorized into several clinical subtypes as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinically isolated syndrome (CIS), often representing the first attack of MS</p><p class="bulletIndent1"><span class="glyph">●</span>Relapsing-remitting MS (RRMS)</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary progressive MS (SPMS)</p><p class="bulletIndent1"><span class="glyph">●</span>Primary progressive MS (PPMS)</p><p></p><p>RRMS is the most common type of MS, and it accounts for 85 to 95 percent of MS at disease onset [<a href="#rid9">9</a>]. Most women planning pregnancies will have CIS and RRMS phenotypes. The different MS phenotypes are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/96029.html" rel="external">"Clinical presentation, course, and prognosis of multiple sclerosis in adults"</a>.)</p><p>In addition, these phenotypes are modified by assessments of disease activity and disease progression over time. Disease activity is determined by clinical relapses or MRI evidence of contrast-enhancing lesions and/or new or unequivocally enlarging lesions on T2-weighted images.</p><p class="headingAnchor" id="H2878032115"><span class="h2">MS activity in pregnancy and postpartum</span><span class="headingEndMark"> — </span>Pregnancy itself is not detrimental for women with MS but rather has a beneficial impact on relapses. Most women with MS have normal fertility, but sexual dysfunction due to MS and fear of getting pregnant may be major obstacles in certain cases. (See  <a class="medical medical_review" href="/d/html/1689.html" rel="external">"Manifestations of multiple sclerosis in adults", section on 'Sexual dysfunction'</a>.)</p><p>The third trimester of pregnancy can have the same potency of effect as most high-efficacy MS disease-modifying therapies. The underlying mechanism is likely related to estriol and progesterone production, a shift from T helper cell 1 phenotype to T helper cell 2 phenotype, and large shifts in gene expression profiles [<a href="#rid53">53</a>]. Thus, for some women with mild to moderate disease, it may be possible to discontinue disease-modifying therapies (DMTs), at least in the second and third trimester, with careful planning in the antepartum period.</p><p>A meta-analysis of 13 studies with 1221 pregnancies published in 2011 concluded that pregnancy is associated with a <strong>decrease</strong> in MS disease activity, while the postpartum period is associated with an <strong>increase</strong> in MS activity [<a href="#rid54">54</a>]. Data from the prospective Pregnancy in Multiple Sclerosis (PRIMS) studies illustrate this conclusion [<a href="#rid55">55,56</a>]. In the first (1998) report of the PRIMS studies, 254 women with MS were followed during 269 pregnancies and for 12 months postpartum [<a href="#rid55">55</a>]. The mean annualized relapse rate (ARR) decreased from 0.7 in the year prior to pregnancy to 0.2 in the third trimester; the ARR then increased to 1.2 in the first three months postpartum, followed by a return to the prepregnancy rate  (<a class="graphic graphic_figure graphicRef138984" href="/d/graphic/138984.html" rel="external">figure 1</a>).</p><p>Subsequent reports have also found a decrease in MS activity during pregnancy and an increase in MS activity during the early postpartum period [<a href="#rid57">57-59</a>].</p><p>The second (2004) PRIMS report, with a two-year postpartum follow-up, analyzed 227 live-born pregnancies from the first report to elucidate any predictors of relapse in the postpartum period [<a href="#rid56">56</a>]. Relapse in the first three months postpartum was most likely in women with an increased relapse rate in the prepregnancy year or an increased relapse rate during pregnancy. However, these factors correctly predicted presence or absence of early postpartum relapse in only 72 percent of women. In this and other studies, predictors for early postpartum relapse included the following [<a href="#rid25">25,56,58,60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Higher ARR in the two years prior to conception</p><p class="bulletIndent1"><span class="glyph">●</span>Relapses occurring in pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>Higher Expanded Disability Status Scale (EDSS) score at conception</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of DMT in the two years prior to conception</p><p></p><p>However, discontinuation of certain DMTs (particularly <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> and <a class="drug drug_general" data-topicid="16078" href="/d/drug information/16078.html" rel="external">fingolimod</a>) has been associated with an overall increased risk of MS relapses, including during pregnancy and postpartum [<a href="#rid61">61-65</a>]. (See  <a class="medical medical_review" href="/d/html/129095.html" rel="external">"Indications for switching or stopping disease-modifying therapy for multiple sclerosis", section on 'Risk of rebound of MS activity'</a>.)</p><p class="headingAnchor" id="H2328247029"><span class="h2">Immunology</span><span class="headingEndMark"> — </span>MS is considered a T helper type 1 (Th1)-dominant disorder, while normal pregnancy is considered a T helper type 2 (Th2)-dominant immune state to allow for maternal immune tolerance of the fetus [<a href="#rid66">66</a>]. During normal pregnancy, the differentiation of CD4+ T cells favors Th2 instead of Th1 dominance of the immune system [<a href="#rid67">67,68</a>]. Th2 cytokine production increases and subsequently decreases the production of the proinflammatory Th1/Th17 cells. The placenta and fetus also secrete cytokines into the maternal bloodstream, which downregulates other cytokine-like substances involved in cell-mediated immunity. The change in immunity may explain the reduced relapse rate during pregnancy.</p><p class="headingAnchor" id="H3758162544"><span class="h2">MS disease progression</span><span class="headingEndMark"> — </span>Despite the reduced MS relapse rate during pregnancy, the cumulative lifetime disability of MS appears to be largely unchanged by pregnancy. For this reason, women may want to consider DMT in the peripartum period to reduce the risk of long-term disability.</p><p>Several epidemiologic investigations have found that long-term disability due to MS is not altered by pregnancy [<a href="#rid69">69-74</a>]. In the PRIMS study, there was no acceleration in the rate of disability or disease progression postpartum [<a href="#rid55">55</a>]. In other reports, women with pregnancies after disease onset show slower progression compared with nulliparous women, based upon the EDSS score [<a href="#rid51">51,75,76</a>].</p><p>The available evidence suggests that pregnancy does not increase the risk of developing MS [<a href="#rid69">69,77-81</a>]. A Danish case-control study found that childbirth within five years before clinical onset was associated with a reduced risk of MS both for one childbirth (OR 0.54, 95% CI 0.41-0.70) and for more than one childbirth (OR 0.68, 95% CI 0.53-0.87) [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H233834587"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy planning and preconception care</strong> – With careful planning, women with multiple sclerosis (MS) can have successful pregnancies without known deleterious effects of pregnancy on mother or infant. Pregnancy has a protective effect against relapse in MS. Counseling during the reproductive years for women with MS is an important aspect of optimizing pregnancy outcomes. The optimal time for pregnancy is when MS symptoms are stable, since MS disease stability is associated with better intrapartum and postpartum outcomes.</p><p></p><p class="bulletIndent1">Women planning pregnancy should avoid alcohol and smoking, eat a balanced diet, take vitamin D supplementation and prenatal vitamins, and prioritize sleep hygiene. Live vaccines should be avoided in pregnant women with MS and given if needed before pregnancy and before certain disease-modifying therapies (DMTs). Preconception planning should also include any adjustment in symptom management medications to avoid potential risks in the first trimester. (See <a class="local">'Preconception planning and care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DMT considerations</strong> – Most experts advise that women may be able to discontinue treatment with DMTs for MS during pregnancy, but it is important to gain control of disease with DMTs before pregnancy, if possible, and to protect women while trying to conceive. Some drugs used to treat MS are clearly contraindicated for use in pregnancy, including most of the oral agents. DMTs that are known teratogens (<a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a> and <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>) and others that are potential teratogens (<a class="drug drug_general" data-topicid="16078" href="/d/drug information/16078.html" rel="external">fingolimod</a>, <a class="drug drug_general" data-topicid="120818" href="/d/drug information/120818.html" rel="external">siponimod</a>, and <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>) are contraindicated for use while pregnant or for women of childbearing potential who are not using reliable contraception. However, DMT discontinuation may lead to an increased intrapartum and postpartum relapse rate, particularly for <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> and fingolimod.</p><p></p><p class="bulletIndent1">For women with highly active MS, the benefit of continuing DMT up to conception or throughout pregnancy may be greater than the risk of fetal harm; reasonable DMT choices in this setting are <a class="drug drug_general" data-topicid="8490" href="/d/drug information/8490.html" rel="external">glatiramer acetate</a>, beta interferons, and <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a>. B-cell depleting therapies can also be given prior to conception, with lasting B-cell depletion long after the drug has cleared the maternal bloodstream. (See <a class="local">'Use of disease-modifying therapies (DMTs)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DMT washout</strong> – For patients who plan to stop DMT before pregnancy, a washout period for DMTs is advised prior to attempting pregnancy to avoid fetal exposure  (<a class="graphic graphic_table graphicRef138581" href="/d/graphic/138581.html" rel="external">table 1</a>). (See <a class="local">'DMT washout'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infertility</strong> – Limited data suggest that MS is not associated with infertility. However, certain medication exposures with assisted reproductive technology have been associated with an increased risk of MS relapse, particularly for women who are off DMT during treatment. (See <a class="local">'Infertility'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MS and pregnancy outcomes</strong> – Most reports suggest that maternal MS does not increase the risk of pregnancy complications or fetal anomalies. (See <a class="local">'Effect of MS on pregnancy outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy and MS activity</strong> – Pregnancy appears to have a protective effect against MS relapses, but there is an increased risk of disease exacerbation in the early postpartum period. (See <a class="local">'Effect of pregnancy on MS disease activity'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol 2023; 22:350.</a></li><li><a class="nounderline abstract_t">McCombe PA, Greer JM. Female reproductive issues in multiple sclerosis. Mult Scler 2013; 19:392.</a></li><li><a class="nounderline abstract_t">Pozzilli C, De Giglio L, Barletta VT, et al. Oral contraceptives combined with interferon β in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2015; 2:e120.</a></li><li><a class="nounderline abstract_t">Jasper EA, Nidey NL, Schweizer ML, Ryckman KK. Gestational vitamin D and offspring risk of multiple sclerosis: a systematic review and meta-analysis. Ann Epidemiol 2020; 43:11.</a></li><li><a class="nounderline abstract_t">ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 495: Vitamin D: Screening and supplementation during pregnancy. Obstet Gynecol 2011; 118:197. Reaffirmed 2019.</a></li><li><a class="nounderline abstract_t">Hollis BW, Johnson D, Hulsey TC, et al. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res 2011; 26:2341.</a></li><li><a class="nounderline abstract_t">Wiley K, Regan A, McIntyre P. Immunisation and pregnancy - who, what, when and why? Aust Prescr 2017; 40:122.</a></li><li><a class="nounderline abstract_t">Alwan S, Yee IM, Dybalski M, et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Mult Scler 2013; 19:351.</a></li><li><a class="nounderline abstract_t">Canibaño B, Deleu D, Mesraoua B, et al. Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. J Drug Assess 2020; 9:20.</a></li><li><a class="nounderline abstract_t">Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502.</a></li><li><a class="nounderline abstract_t">Robertson NP, O'Riordan JI, Chataway J, et al. Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. Lancet 1997; 349:1587.</a></li><li><a class="nounderline abstract_t">Ebers GC, Yee IM, Sadovnick AD, Duquette P. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. Ann Neurol 2000; 48:927.</a></li><li><a class="nounderline abstract_t">International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 2019; 365.</a></li><li><a class="nounderline abstract_t">Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother 2013; 13:3.</a></li><li><a class="nounderline abstract_t">Rasmussen PV, Magyari M, Moberg JY, et al. Patient awareness about family planning represents a major knowledge gap in multiple sclerosis. Mult Scler Relat Disord 2018; 24:129.</a></li><li><a class="nounderline abstract_t">Ghezzi A, Annovazzi P, Portaccio E, et al. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Rev Clin Immunol 2013; 9:683.</a></li><li><a class="nounderline abstract_t">Coyle PK, Oh J, Magyari M, et al. Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review. Mult Scler Relat Disord 2019; 32:54.</a></li><li><a class="nounderline abstract_t">Alroughani R, Altintas A, Al Jumah M, et al. Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. Mult Scler Int 2016; 2016:1034912.</a></li><li><a class="nounderline abstract_t">Freedman MS, Devonshire V, Duquette P, et al. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci 2020; 47:437.</a></li><li><a class="nounderline abstract_t">Bove RM, Houtchens MK. Pregnancy Management in Multiple Sclerosis and Other Demyelinating Diseases. Continuum (Minneap Minn) 2022; 28:12.</a></li><li><a class="nounderline abstract_t">Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012; 79:1130.</a></li><li><a class="nounderline abstract_t">Coyle PK, Sinclair SM, Scheuerle AE, et al. Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open 2014; 4:e004536.</a></li><li><a class="nounderline abstract_t">MacDonald SC, McElrath TF, Hernández-Díaz S. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis. Pharmacoepidemiol Drug Saf 2019; 28:556.</a></li><li><a class="nounderline abstract_t">Yeh WZ, Widyastuti PA, Van der Walt A, et al. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology 2021; 96:e2989.</a></li><li><a class="nounderline abstract_t">Fragoso YD, Boggild M, Macias-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg 2013; 115:154.</a></li><li><a class="nounderline abstract_t">Hellwig K, Gold R. Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J Neurol 2011; 258:502.</a></li><li><a class="nounderline abstract_t">Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol 2010; 257:2020.</a></li><li><a class="nounderline abstract_t">Hellwig K, Duarte Caron F, Wicklein EM, et al. Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure. Ther Adv Neurol Disord 2020; 13:1756286420910310.</a></li><li><a class="nounderline abstract_t">Portaccio E, Annovazzi P, Ghezzi A, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology 2018; 90:e823.</a></li><li><a class="nounderline abstract_t">Friend S, Richman S, Bloomgren G, et al. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol 2016; 16:150.</a></li><li><a class="nounderline abstract_t">Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler 2015; 21:198.</a></li><li><a class="nounderline abstract_t">Krysko KM, Bove R, Dobson R, et al. Treatment of Women with Multiple Sclerosis Planning Pregnancy. Curr Treat Options Neurol 2021; 23:11.</a></li><li><a class="nounderline abstract_t">Coyle PK. Multiple sclerosis and pregnancy prescriptions. Expert Opin Drug Saf 2014; 13:1565.</a></li><li><a class="nounderline abstract_t">Smith JB, Hellwig K, Fink K, et al. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm 2020; 7.</a></li><li><a class="nounderline abstract_t">Gross RH, Corboy JR. Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies. Continuum (Minneap Minn) 2019; 25:715.</a></li><li class="breakAll">Teriflunomide prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202992s013s015lbl.pdf (Accessed on October 27, 2023).</li><li><a class="nounderline abstract_t">Lamaita R, Melo C, Laranjeira C, et al. Multiple Sclerosis in Pregnancy and its Role in Female Fertility: A Systematic Review. JBRA Assist Reprod 2021; 25:493.</a></li><li><a class="nounderline abstract_t">Roux T, Courtillot C, Debs R, et al. Fecundity in women with multiple sclerosis: an observational mono-centric study. J Neurol 2015; 262:957.</a></li><li><a class="nounderline abstract_t">Hellwig K. Pregnancy in multiple sclerosis. Eur Neurol 2014; 72 Suppl 1:39.</a></li><li><a class="nounderline abstract_t">Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord 2016; 9:198.</a></li><li><a class="nounderline abstract_t">Thöne J, Kollar S, Nousome D, et al. Serum anti-Müllerian hormone levels in reproductive-age women with relapsing-remitting multiple sclerosis. Mult Scler 2015; 21:41.</a></li><li><a class="nounderline abstract_t">McCombe PA, Stenager E. Female infertility and multiple sclerosis: is this an issue? Mult Scler 2015; 21:5.</a></li><li><a class="nounderline abstract_t">Graves JS, Henry RG, Cree BAC, et al. Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology 2018; 90:e254.</a></li><li><a class="nounderline abstract_t">Lu E, Zhu F, Zhao Y, et al. Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs. CNS Drugs 2014; 28:475.</a></li><li><a class="nounderline abstract_t">Cavalla P, Rovei V, Masera S, et al. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol Sci 2006; 27:231.</a></li><li><a class="nounderline abstract_t">Correale J, Farez MF, Ysrraelit MC. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol 2012; 72:682.</a></li><li><a class="nounderline abstract_t">Bove R, Rankin K, Lin C, et al. Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis. Mult Scler 2020; 26:1410.</a></li><li><a class="nounderline abstract_t">Mueller BA, Zhang J, Critchlow CW. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis. Am J Obstet Gynecol 2002; 186:446.</a></li><li><a class="nounderline abstract_t">Andersen JB, Kopp TI, Sellebjerg F, Magyari M. Pregnancy-Related and Perinatal Outcomes in Women With Multiple Sclerosis: A Nationwide Danish Cross-sectional Study. Neurol Clin Pract 2021; 11:280.</a></li><li><a class="nounderline abstract_t">Kelly VM, Nelson LM, Chakravarty EF. Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology 2009; 73:1831.</a></li><li><a class="nounderline abstract_t">Ramagopalan SV, Guimond C, Criscuoli M, et al. Congenital abnormalities and multiple sclerosis. BMC Neurol 2010; 10:115.</a></li><li><a class="nounderline abstract_t">Dahl J, Myhr KM, Daltveit AK, et al. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology 2005; 65:1961.</a></li><li><a class="nounderline abstract_t">Voskuhl R, Momtazee C. Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding. Neurotherapeutics 2017; 14:974.</a></li><li><a class="nounderline abstract_t">Finkelsztejn A, Brooks JB, Paschoal FM Jr, Fragoso YD. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG 2011; 118:790.</a></li><li><a class="nounderline abstract_t">Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339:285.</a></li><li><a class="nounderline abstract_t">Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127:1353.</a></li><li><a class="nounderline abstract_t">Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol 2014; 124:1157.</a></li><li><a class="nounderline abstract_t">Hughes SE, Spelman T, Gray OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 2014; 20:739.</a></li><li><a class="nounderline abstract_t">Houtchens MK, Edwards NC, Phillips AL. Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology 2018; 91:e1570.</a></li><li><a class="nounderline abstract_t">Coyle PK. Multiple sclerosis in pregnancy. Continuum (Minneap Minn) 2014; 20:42.</a></li><li><a class="nounderline abstract_t">Bsteh G, Algrang L, Hegen H, et al. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria. Mult Scler 2020; 26:69.</a></li><li><a class="nounderline abstract_t">Portaccio E, Moiola L, Martinelli V, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology 2018; 90:e832.</a></li><li><a class="nounderline abstract_t">Alroughani R, Alowayesh MS, Ahmed SF, et al. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology 2018; 90:e840.</a></li><li><a class="nounderline abstract_t">Berenguer-Ruiz L, Gimenez-Martinez J, Palazón-Bru A, Sempere AP. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy. J Neurol 2019; 266:2512.</a></li><li><a class="nounderline abstract_t">Khalid F, Healy BC, Dupuy SL, et al. Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis. J Neurol Sci 2018; 392:94.</a></li><li><a class="nounderline abstract_t">Qiu K, He Q, Chen X, et al. Pregnancy-Related Immune Changes and Demyelinating Diseases of the Central Nervous System. Front Neurol 2019; 10:1070.</a></li><li><a class="nounderline abstract_t">Raghupathy R, Kalinka J. Cytokine imbalance in pregnancy complications and its modulation. Front Biosci 2008; 13:985.</a></li><li><a class="nounderline abstract_t">Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14:353.</a></li><li><a class="nounderline abstract_t">Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 1995; 118 ( Pt 1):253.</a></li><li><a class="nounderline abstract_t">Verdru P, Theys P, D'Hooghe MB, Carton H. Pregnancy and multiple sclerosis: the influence on long term disability. Clin Neurol Neurosurg 1994; 96:38.</a></li><li><a class="nounderline abstract_t">Ramagopalan S, Yee I, Byrnes J, et al. Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2012; 83:793.</a></li><li><a class="nounderline abstract_t">Koch M, Uyttenboogaart M, Heersema D, et al. Parity and secondary progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80:676.</a></li><li><a class="nounderline abstract_t">Roullet E, Verdier-Taillefer MH, Amarenco P, et al. Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. J Neurol Neurosurg Psychiatry 1993; 56:1062.</a></li><li><a class="nounderline abstract_t">Gavoille A, Rollot F, Casey R, et al. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference. Neurology 2023; 100:e1296.</a></li><li><a class="nounderline abstract_t">D'hooghe MB, Nagels G, Uitdehaag BM. Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry 2010; 81:38.</a></li><li><a class="nounderline abstract_t">Masera S, Cavalla P, Prosperini L, et al. Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis. Mult Scler 2015; 21:1291.</a></li><li><a class="nounderline abstract_t">Ponsonby AL, Lucas RM, van der Mei IA, et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study. Neurology 2012; 78:867.</a></li><li><a class="nounderline abstract_t">Operskalski EA, Visscher BR, Malmgren RM, Detels R. A case-control study of multiple sclerosis. Neurology 1989; 39:825.</a></li><li><a class="nounderline abstract_t">Hernán MA, Hohol MJ, Olek MJ, et al. Oral contraceptives and the incidence of multiple sclerosis. Neurology 2000; 55:848.</a></li><li><a class="nounderline abstract_t">Alonso A, Jick SS, Olek MJ, et al. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 2005; 62:1362.</a></li><li><a class="nounderline abstract_t">Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol 1998; 105:1296.</a></li><li><a class="nounderline abstract_t">Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS. Reproduction and the risk of multiple sclerosis. Mult Scler 2013; 19:1604.</a></li></ol></div><div id="topicVersionRevision">Topic 135221 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36931808" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Family planning considerations in people with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733837" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Female reproductive issues in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26140279" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Oral contraceptives combined with interferonβin multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32014337" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Gestational vitamin D and offspring risk of multiple sclerosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21691184" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : ACOG Committee Opinion No. 495: Vitamin D: Screening and supplementation during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21706518" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28947846" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Immunisation and pregnancy - who, what, when and why?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22760102" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reproductive decision making after the diagnosis of multiple sclerosis (MS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32128285" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18970977" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9174560" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11117550" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31604244" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24289836" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Environmental factors in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30005355" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Patient awareness about family planning represents a major knowledge gap in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899239" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31030020" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28078140" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32654681" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35133309" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pregnancy Management in Multiple Sclerosis and Other Demyelinating Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22933738" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24821713" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Final results from the Betaseron (interferonβ-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30834654" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33879599" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22633835" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20878174" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20625758" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32201504" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29438046" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27552976" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evaluation of pregnancy outcomes from the Tysabri®(natalizumab) pregnancy exposure registry: a global, observational, follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25159275" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33814892" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of Women with Multiple Sclerosis Planning Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25406727" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Multiple sclerosis and pregnancy prescriptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32358226" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Rituximab, MS, and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31162313" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31162313" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34061482" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Multiple Sclerosis in Pregnancy and its Role in Female Fertility: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25673128" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Fecundity in women with multiple sclerosis: an observational mono-centric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25278125" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pregnancy in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27134675" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Management of women with multiple sclerosis through pregnancy and after childbirth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25145691" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Serum anti-Müllerian hormone levels in reproductive-age women with relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25583835" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Female infertility and multiple sclerosis: is this an issue?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29273686" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ovarian aging is associated with gray matter volume and disability in women with MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24643915" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16998725" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Fertility in patients with multiple sclerosis: current knowledge and future perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23034952" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Increase in multiple sclerosis activity after assisted reproduction technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31368394" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904605" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34484927" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pregnancy-Related and Perinatal Outcomes in Women With Multiple Sclerosis: A Nationwide Danish Cross-sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19923552" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Obstetric outcomes in women with multiple sclerosis and epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21080921" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Congenital abnormalities and multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380620" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pregnancy, delivery, and birth outcome in women with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28766273" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21401856" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9682040" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15130950" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25415167" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24107309" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Predictors and dynamics of postpartum relapses in women with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30266887" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24492810" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Multiple sclerosis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30507345" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29438041" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29429970" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31256279" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30031994" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31649614" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pregnancy-Related Immune Changes and Demyelinating Diseases of the Central Nervous System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17981605" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cytokine imbalance in pregnancy complications and its modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8363725" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7895009" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8187380" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pregnancy and multiple sclerosis: the influence on long term disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22626946" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19448093" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Parity and secondary progression in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8410003" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36564207" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19939856" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Long-term effects of childbirth in MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25533293" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22402857" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2725877" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A case-control study of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10994007" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Oral contraceptives and the incidence of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157743" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Recent use of oral contraceptives and the risk of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9883921" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The influence of oral contraceptives on the risk of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23508651" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Reproduction and the risk of multiple sclerosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
